

# Mariano Barbacid

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3104127/publications.pdf>

Version: 2024-02-01

148  
papers

41,631  
citations

6486

82  
h-index

9865

146  
g-index

149  
all docs

149  
docs citations

149  
times ranked

39722  
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting <i>KRAS</i> mutant lung cancer: light at the end of the tunnel. <i>Molecular Oncology</i> , 2022, 16, 1057-1071.	2.1	23
2	KSR induces RAS-independent MAPK pathway activation and modulates the efficacy of KRAS inhibitors. <i>Molecular Oncology</i> , 2022, 16, 3066-3081.	2.1	10
3	Combined Inhibition of FOSL-1 and YAP Using siRNA-Lipoplexes Reduces the Growth of Pancreatic Tumor. <i>Cancers</i> , 2022, 14, 3102.	1.7	4
4	Dynamic Regulation of Expression of KRAS and Its Effectors Determines the Ability to Initiate Tumorigenesis in Pancreatic Acinar Cells. <i>Cancer Research</i> , 2021, 81, 2679-2689.	0.4	11
5	RAF1 kinase activity is dispensable for KRAS/p53 mutant lung tumor progression. <i>Cancer Cell</i> , 2021, 39, 294-296.	7.7	18
6	KRAS4A induces metastatic lung adenocarcinomas in vivo in the absence of the KRAS4B isoform. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	9
7	Definitive evidence for Club cells as progenitors for mutant <i>Kras/Trp53</i> -deficient lung cancer. <i>International Journal of Cancer</i> , 2021, 149, 1670-1682.	2.3	5
8	TARGETING KRAS SIGNALING IN PANCREATIC CANCER.. <i>Pancreatology</i> , 2020, 20, e18.	0.5	0
9	Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 24415-24426.	3.3	15
10	Requirement for epithelial p38 $\beta$ in KRAS-driven lung tumor progression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 2588-2596.	3.3	16
11	Targeting the MAPK Pathway in KRAS-Driven Tumors. <i>Cancer Cell</i> , 2020, 37, 543-550.	7.7	253
12	Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF. <i>Cancer Cell</i> , 2019, 35, 573-587.e6.	7.7	75
13	RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling. <i>Nature Medicine</i> , 2019, 25, 284-291.	15.2	125
14	Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties. <i>Cancer Discovery</i> , 2018, 8, 648-661.	7.7	97
15	ERF deletion rescues RAS deficiency in mouse embryonic stem cells. <i>Genes and Development</i> , 2018, 32, 568-576.	2.7	13
16	c-RAF Ablation Induces Regression of Advanced <i>Kras/Trp53</i> Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK Signaling. <i>Cancer Cell</i> , 2018, 33, 217-228.e4.	7.7	93
17	Saa3 is a key mediator of the protumorigenic properties of cancer-associated fibroblasts in pancreatic tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E1147-E1156.	3.3	128
18	The Capicua tumor suppressor: a gatekeeper of Ras signaling in development and cancer. <i>Cell Cycle</i> , 2018, 17, 702-711.	1.3	36

#	ARTICLE	IF	CITATIONS
19	Genetically Engineered Mouse Models of K-Ras-Driven Lung and Pancreatic Tumors: Validation of Therapeutic Targets. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2018, 8, a031542.	2.9	19
20	Cyclin E1 and cyclin-dependent kinase 2 are critical for initiation, but not for progression of hepatocellular carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 9282-9287.	3.3	68
21	Afatinib restrains K-RAS-driven lung tumorigenesis. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	99
22	Management of Cancer in the Older Age Person: An Approach to Complex Medical Decisions. <i>Oncologist</i> , 2017, 22, 335-342.	1.9	39
23	Cyclin-Dependent Kinase 4 Regulates Adult Neural Stem Cell Proliferation and Differentiation in Response to Insulin. <i>Stem Cells</i> , 2017, 35, 2403-2416.	1.4	29
24	Inactivation of Capicua in adult mice causes T-cell lymphoblastic lymphoma. <i>Genes and Development</i> , 2017, 31, 1456-1468.	2.7	41
25	Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. <i>Nature</i> , 2017, 548, 234-238.	13.7	394
26	A Braf kinase-inactive mutant induces lung adenocarcinoma. <i>Nature</i> , 2017, 548, 239-243.	13.7	85
27	Severe Intellectual Disability and Enhanced Gamma-Aminobutyric Acidergic Synaptogenesis in a Novel Model of Rare RASopathies. <i>Biological Psychiatry</i> , 2017, 81, 179-192.	0.7	30
28	H-Ras and K-Ras Oncoproteins Induce Different Tumor Spectra When Driven by the Same Regulatory Sequences. <i>Cancer Research</i> , 2017, 77, 707-718.	0.4	21
29	A new mode of DNA binding distinguishes Capicua from other HMG-box factors and explains its mutation patterns in cancer. <i>PLoS Genetics</i> , 2017, 13, e1006622.	1.5	45
30	KRAS-driven lung adenocarcinoma: combined DDR1/Notch inhibition as an effective therapy. <i>ESMO Open</i> , 2016, 1, e000076.	2.0	19
31	The European Cancer Patient's Bill of Rights, update and implementation 2016. <i>ESMO Open</i> , 2016, 1, e000127.	2.0	36
32	Ras and p53: An unsuspected liaison. <i>Molecular and Cellular Oncology</i> , 2016, 3, e996001.	0.3	2
33	Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma. <i>Nature Medicine</i> , 2016, 22, 270-277.	15.2	150
34	Modeling K-Ras-driven lung adenocarcinoma in mice: preclinical validation of therapeutic targets. <i>Journal of Molecular Medicine</i> , 2016, 94, 121-135.	1.7	12
35	H-Ras Distribution and Signaling in Plasma Membrane Microdomains Are Regulated by Acylation and Deacylation Events. <i>Molecular and Cellular Biology</i> , 2015, 35, 1898-1914.	1.1	30
36	Functional Reprogramming of Polyploidization in Megakaryocytes. <i>Developmental Cell</i> , 2015, 32, 155-167.	3.1	47

#	ARTICLE	IF	CITATIONS
37	Therapeutic inhibition of TRF 1 impairs the growth of p53-deficient K-Ras <sup>G12V</sup> induced lung cancer by induction of telomeric DNA damage. <i>EMBO Molecular Medicine</i> , 2015, 7, 930-949.	3.3	45
38	Identification of cancer initiating cells in K-Ras driven lung adenocarcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 255-260.	3.3	151
39	A Catalyst for Change: The European Cancer Patient's Bill of Rights. <i>Oncologist</i> , 2014, 19, 217-224.	1.9	35
40	K-Ras <sup>V14I</sup> recapitulates Noonan syndrome in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 16395-16400.	3.3	67
41	Modeling Lung Cancer Evolution and Preclinical Response by Orthotopic Mouse Allografts. <i>Cancer Research</i> , 2014, 74, 5978-5988.	0.4	30
42	Genetic Characterization of the Role of the Cip/Kip Family of Proteins as Cyclin-Dependent Kinase Inhibitors and Assembly Factors. <i>Molecular and Cellular Biology</i> , 2014, 34, 1452-1459.	1.1	28
43	Concurrent deletion of cyclin E1 and cyclin-dependent kinase 2 in hepatocytes inhibits DNA replication and liver regeneration in mice. <i>Hepatology</i> , 2014, 59, 651-660.	3.6	41
44	Loss of p53 induces cell proliferation via Ras-independent activation of the Raf/Mek/Erk signaling pathway. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 15155-15160.	3.3	80
45	Ras in epidermal proliferation. <i>Oncotarget</i> , 2014, 5, 5194-5195.	0.8	0
46	Genetically engineered mouse models of pancreatic adenocarcinoma. <i>Molecular Oncology</i> , 2013, 7, 232-247.	2.1	140
47	Mouse models of cancer. <i>Molecular Oncology</i> , 2013, 7, 143-145.	2.1	14
48	Genetic analysis of Ras genes in epidermal development and tumorigenesis. <i>Small GTPases</i> , 2013, 4, 236-241.	0.7	8
49	Lkb1 Loss Promotes Tumor Progression of BRAFV600E-Induced Lung Adenomas. <i>PLoS ONE</i> , 2013, 8, e66933.	1.1	11
50	Genetic inactivation of Cdk7 leads to cell cycle arrest and induces premature aging due to adult stem cell exhaustion. <i>EMBO Journal</i> , 2012, 31, 2498-2510.	3.5	85
51	EGF Receptor Signaling Is Essential for K-Ras Oncogene-Driven Pancreatic Ductal Adenocarcinoma. <i>Cancer Cell</i> , 2012, 22, 318-330.	7.7	339
52	Rapid identification of ETP-46992, orally bioavailable PI3K inhibitor, selective versus mTOR. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 5208-5214.	1.0	19
53	Opening a New GATAWay for Treating KRAS-Driven Lung Tumors. <i>Cancer Cell</i> , 2012, 21, 598-600.	7.7	8
54	Identification of ETP-46321, a potent and orally bioavailable PI3K $\pm$ , $\hat{\imath}$ inhibitor. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 3460-3466.	1.0	24

#	ARTICLE	IF	CITATIONS
55	Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. <i>Nature Structural and Molecular Biology</i> , 2011, 18, 1331-1335.	3.6	342
56	A Pericyte Origin of Spinal Cord Scar Tissue. <i>Science</i> , 2011, 333, 238-242.	6.0	711
57	Mutant K-Ras Activation of the Proapoptotic MST2 Pathway Is Antagonized by Wild-Type K-Ras. <i>Molecular Cell</i> , 2011, 44, 893-906.	4.5	127
58	c-Raf, but Not B-Raf, Is Essential for Development of K-Ras Oncogene-Driven Non-Small Cell Lung Carcinoma. <i>Cancer Cell</i> , 2011, 19, 652-663.	7.7	260
59	Pancreatitis-Induced Inflammation Contributes to Pancreatic Cancer by Inhibiting Oncogene-Induced Senescence. <i>Cancer Cell</i> , 2011, 19, 728-739.	7.7	437
60	Cdk6-Dependent Regulation of G1 Length Controls Adult Neurogenesis. <i>Stem Cells</i> , 2011, 29, 713-724.	1.4	54
61	Constitutive activation of B-Raf in the mouse germ line provides a model for human cardio-facio-cutaneous syndrome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 5015-5020.	3.3	61
62	Toll-like Receptor-4 (TLR4) Down-regulates MicroRNA-107, Increasing Macrophage Adhesion via Cyclin-dependent Kinase 6. <i>Journal of Biological Chemistry</i> , 2011, 286, 25531-25539.	1.6	56
63	A Synthetic Lethal Interaction between K-Ras Oncogenes and Cdk4 Unveils a Therapeutic Strategy for Non-small Cell Lung Carcinoma. <i>Cancer Cell</i> , 2010, 18, 63-73.	7.7	373
64	DYRK1B-dependent autocrine-to-paracrine shift of Hedgehog signaling by mutant RAS. <i>Nature Structural and Molecular Biology</i> , 2010, 17, 718-725.	3.6	141
65	Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival. <i>EMBO Journal</i> , 2010, 29, 1091-1104.	3.5	267
66	Cdk2 suppresses cellular senescence induced by the c-myc oncogene. <i>Nature Cell Biology</i> , 2010, 12, 54-59.	4.6	218
67	Overall Cdk activity modulates the DNA damage response in mammalian cells. <i>Journal of Cell Biology</i> , 2009, 187, 773-780.	2.3	53
68	Cell cycle, CDKs and cancer: a changing paradigm. <i>Nature Reviews Cancer</i> , 2009, 9, 153-166.	12.8	3,070
69	Postnatal Schwann cell proliferation but not myelination is strictly and uniquely dependent on cyclin-dependent kinase 4 (cdk4). <i>Molecular and Cellular Neurosciences</i> , 2008, 37, 519-527.	1.0	26
70	CDK inhibitors in cancer therapy: what is next?. <i>Trends in Pharmacological Sciences</i> , 2008, 29, 16-21.	4.0	234
71	A mouse model for Costello syndrome reveals an Ang II-mediated hypertensive condition. <i>Journal of Clinical Investigation</i> , 2008, 118, 2169-79.	3.9	97
72	Returning Home. <i>Cell</i> , 2007, 129, 641-644.	13.5	1

#	ARTICLE	IF	CITATIONS
73	Cell cycle kinases in cancer. <i>Current Opinion in Genetics and Development</i> , 2007, 17, 60-65.	1.5	300
74	Mice thrive without Cdk4 and Cdk2. <i>Molecular Oncology</i> , 2007, 1, 72-83.	2.1	99
75	p38 <sup>Î±</sup> MAP kinase is essential in lung stem and progenitor cell proliferation and differentiation. <i>Nature Genetics</i> , 2007, 39, 750-758.	9.4	278
76	Cdk1 is sufficient to drive the mammalian cell cycle. <i>Nature</i> , 2007, 448, 811-815.	13.7	888
77	Chronic Pancreatitis Is Essential for Induction of Pancreatic Ductal Adenocarcinoma by K-Ras Oncogenes in Adult Mice. <i>Cancer Cell</i> , 2007, 11, 291-302.	7.7	1,042
78	Rapid Growth of Invasive Metastatic Melanoma in Carcinogen-Treated Hepatocyte Growth Factor/Scatter Factor-Transgenic Mice Carrying an Oncogenic CDK4 Mutation. <i>American Journal of Pathology</i> , 2006, 169, 665-672.	1.9	53
79	Is Cyclin D1-CDK4 kinase a bona fide cancer target?. <i>Cancer Cell</i> , 2006, 9, 2-4.	7.7	96
80	Evaluation of genetic melanoma vaccines in cdk4-mutant mice provides evidence for immunological tolerance against autochthonous melanomas in the skin. <i>International Journal of Cancer</i> , 2006, 118, 373-380.	2.3	12
81	Loss of Apc allows phenotypic manifestation of the transforming properties of an endogenous K-ras oncogene in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 14122-14127.	3.3	181
82	Spontaneous and UV Radiation-Induced Multiple Metastatic Melanomas in Cdk4R24C/R24C/TPras Mice. <i>Cancer Research</i> , 2006, 66, 2946-2952.	0.4	52
83	Senescence in premalignant tumours. <i>Nature</i> , 2005, 436, 642-642.	13.7	1,280
84	Protein farnesyltransferase in embryogenesis, adult homeostasis, and tumor development. <i>Cancer Cell</i> , 2005, 7, 313-324.	7.7	106
85	Cdk2 is dispensable for cell cycle inhibition and tumor suppression mediated by p27Kip1 and p21Cip1. <i>Cancer Cell</i> , 2005, 7, 591-598.	7.7	205
86	Mammalian cyclin-dependent kinases. <i>Trends in Biochemical Sciences</i> , 2005, 30, 630-641.	3.7	1,069
87	Cooperation between Cdk4 and p27kip1 in Tumor Development: A Preclinical Model to Evaluate Cell Cycle Inhibitors with Therapeutic Activity. <i>Cancer Research</i> , 2005, 65, 3846-3852.	0.4	55
88	Cdk4 promotes adipogenesis through PPAR <sup>Î³</sup> activation. <i>Cell Metabolism</i> , 2005, 2, 239-249.	7.2	136
89	The European dimension for the mouse genome mutagenesis program. <i>Nature Genetics</i> , 2004, 36, 925-927.	9.4	195
90	Mammalian Cells Cycle without the D-Type Cyclin-Dependent Kinases Cdk4 and Cdk6. <i>Cell</i> , 2004, 118, 493-504.	13.5	719

#	ARTICLE	IF	CITATIONS
91	Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. <i>Cancer Cell</i> , 2003, 4, 111-120.	7.7	518
92	Genetic rescue of Cdk4 null mice restores pancreatic $\hat{I}^2$ -cell proliferation but not homeostatic cell number. <i>Oncogene</i> , 2003, 22, 5261-5269.	2.6	118
93	Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. <i>Nature Genetics</i> , 2003, 35, 25-31.	9.4	802
94	RAS oncogenes: the first 30 years. <i>Nature Reviews Cancer</i> , 2003, 3, 459-465.	12.8	1,597
95	Compensation between Vav-1 and Vav-2 in B cell development and antigen receptor signaling. <i>Nature Immunology</i> , 2001, 2, 548-555.	7.0	156
96	To cycle or not to cycle: a critical decision in cancer. <i>Nature Reviews Cancer</i> , 2001, 1, 222-231.	12.8	1,289
97	Control of Spermatogenesis in Mice by the Cyclin D-Dependent Kinase Inhibitors p18 Ink4c and p19 Ink4d. <i>Molecular and Cellular Biology</i> , 2001, 21, 3244-3255.	1.1	103
98	Genetic Analysis of Ephrin-A2 and Ephrin-A5 Shows Their Requirement in Multiple Aspects of Retinocollicular Mapping. <i>Neuron</i> , 2000, 25, 563-574.	3.8	450
99	Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in $\hat{I}^2$ -islet cell hyperplasia. <i>Nature Genetics</i> , 1999, 22, 44-52.	9.4	711
100	Nerve Dependency of Developing and Mature Sensory Receptor Cells. <i>Annals of the New York Academy of Sciences</i> , 1998, 855, 14-27.	1.8	20
101	Corneal innervation and sensitivity to noxious stimuli in <i>trkA</i> knockout mice. <i>European Journal of Neuroscience</i> , 1998, 10, 146-152.	1.2	82
102	Ephrin-A5 (AL-1/RAGS) Is Essential for Proper Retinal Axon Guidance and Topographic Mapping in the Mammalian Visual System. <i>Neuron</i> , 1998, 20, 235-243.	3.8	428
103	Topographic Guidance Labels in a Sensory Projection to the Forebrain. <i>Neuron</i> , 1998, 21, 1303-1313.	3.8	255
104	The combined effects of <i>trkB</i> and <i>trkC</i> mutations on the innervation of the inner ear. <i>International Journal of Developmental Neuroscience</i> , 1998, 16, 493-505.	0.7	59
105	<i>TrkB</i> and <i>TrkC</i> Signaling Are Required for Maturation and Synaptogenesis of Hippocampal Connections. <i>Journal of Neuroscience</i> , 1998, 18, 7336-7350.	1.7	230
106	A Role for <i>TrkA</i> during Maturation of Striatal and Basal Forebrain Cholinergic Neurons <i>In Vivo</i> . <i>Journal of Neuroscience</i> , 1997, 17, 7644-7654.	1.7	133
107	<i>TrkB</i> Signaling Is Required for Postnatal Survival of CNS Neurons and Protects Hippocampal and Motor Neurons from Axotomy-Induced Cell Death. <i>Journal of Neuroscience</i> , 1997, 17, 3623-3633.	1.7	182
108	Severe Sensory Deficits but Normal CNS Development in Newborn Mice Lacking <i>TrkB</i> and <i>TrkC</i> Tyrosine Protein Kinase Receptors. <i>European Journal of Neuroscience</i> , 1997, 9, 2045-2056.	1.2	124

#	ARTICLE	IF	CITATIONS
109	A giant protein that stimulates guanine nucleotide exchange on ARF1 and Rab proteins forms a cytosolic ternary complex with clathrin and Hsp70. <i>Oncogene</i> , 1997, 15, 1-6.	2.6	61
110	Cbl-b, a member of the Sli-1/c-Cbl protein family, inhibits Vav-mediated c-Jun N-terminal kinase activation. <i>Oncogene</i> , 1997, 15, 2511-2520.	2.6	87
111	Genetic analysis of the role of Eph receptors in the development of the mammalian nervous system. <i>Cell and Tissue Research</i> , 1997, 290, 209-215.	1.5	17
112	Development of Highly Potent Inhibitors of Ras Farnesyltransferase Possessing Cellular and <i>In Vivo</i> Activity. <i>Journal of Medicinal Chemistry</i> , 1996, 39, 224-236.	2.9	82
113	Synchronous Onset of NGF and TrkA Survival Dependence in Developing Dorsal Root Ganglia. <i>Journal of Neuroscience</i> , 1996, 16, 4662-4672.	1.7	154
114	TrkA, But Not TrkC, Receptors Are Essential for Survival of Sympathetic Neurons <i>In Vivo</i> . <i>Journal of Neuroscience</i> , 1996, 16, 6208-6218.	1.7	180
115	Mice Lacking Brain-Derived Neurotrophic Factor Exhibit Visceral Sensory Neuron Losses Distinct from Mice Lacking NT4 and Display a Severe Developmental Deficit in Control of Breathing. <i>Journal of Neuroscience</i> , 1996, 16, 5361-5371.	1.7	342
116	Renal agenesis and the absence of enteric neurons in mice lacking GDNF. <i>Nature</i> , 1996, 382, 70-73.	13.7	1,154
117	Ras farnesylation as a target for novel antitumor agents: Potent and selective farnesyl diphosphate analog inhibitors of farnesyltransferase. <i>Drug Development Research</i> , 1995, 34, 121-137.	1.4	68
118	Defective T-cell receptor signalling and positive selection of Vav-deficient CD4 <sup>+</sup> CD8 <sup>+</sup> thymocytes. <i>Nature</i> , 1995, 374, 474-476.	13.7	299
119	Phosphinyl Acid-Based Bisubstrate Analog Inhibitors of Farnesyl Protein Transferase. <i>Journal of Medicinal Chemistry</i> , 1995, 38, 435-442.	2.9	79
120	Neurotrophic factors and their receptors. <i>Current Opinion in Cell Biology</i> , 1995, 7, 148-155.	2.6	539
121	Structural and Functional Properties of the TRK Family of Neurotrophin Receptors. <i>Annals of the New York Academy of Sciences</i> , 1995, 766, 442-458.	1.8	240
122	The Trk family of neurotrophin receptors. <i>Journal of Neurobiology</i> , 1994, 25, 1386-1403.	3.7	1,187
123	Severe sensory and sympathetic neuropathies in mice carrying a disrupted Trk/NGF receptor gene. <i>Nature</i> , 1994, 368, 246-249.	13.7	932
124	Disruption of the neurotrophin-3 receptor gene <i>trkC</i> eliminates Ia muscle afferents and results in abnormal movements. <i>Nature</i> , 1994, 368, 249-251.	13.7	607
125	High-affinity nerve growth factor receptor (Trk) immunoreactivity is localized in cholinergic neurons of the basal forebrain and striatum in the adult rat brain. <i>Brain Research</i> , 1993, 612, 330-335.	1.1	153
126	Similarities and differences in the way neurotrophins interact with the Trk receptors in neuronal and nonneuronal cells. <i>Neuron</i> , 1993, 10, 137-149.	3.8	524



#	ARTICLE	IF	CITATIONS
127	Nerve growth factor mediates signal transduction through trk homodimer receptors. <i>Neuron</i> , 1992, 9, 1067-1079.	3.8	452
128	The trk B tyrosine protein kinase is a receptor for neurotrophin-4. <i>Neuron</i> , 1992, 8, 947-956.	3.8	306
129	Product of vav proto-oncogene defines a new class of tyrosine protein kinase substrates. <i>Nature</i> , 1992, 356, 68-71.	13.7	320
130	The trk tyrosine protein kinase mediates the mitogenic properties of nerve growth factor and neurotrophin-3. <i>Cell</i> , 1991, 66, 173-183.	13.5	521
131	The trk proto-oncogene encodes a receptor for nerve growth factor. <i>Cell</i> , 1991, 65, 189-197.	13.5	1,368
132	trkC, a new member of the trk family of tyrosine protein kinases, is a receptor for neurotrophin-3. <i>Cell</i> , 1991, 66, 967-979.	13.5	1,040
133	The trkB tyrosine protein kinase is a receptor for brain-derived neurotrophic factor and neurotrophin-3. <i>Cell</i> , 1991, 66, 395-403.	13.5	881
134	The human VAV proto-oncogene maps to chromosome region 19p12?19p13.2. <i>Human Genetics</i> , 1990, 86, 65-8.	1.8	21
135	The trkB tyrosine protein kinase gene codes for a second neurogenic receptor that lacks the catalytic kinase domain. <i>Cell</i> , 1990, 61, 647-656.	13.5	712
136	A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences. <i>Nature</i> , 1986, 319, 743-748.	13.7	755
137	Mutagens, oncogenes and cancer. <i>Trends in Genetics</i> , 1986, 2, 188-192.	2.9	84
138	Oncogenes and human cancer: cause or consequence?. <i>Carcinogenesis</i> , 1986, 7, 1037-1042.	1.3	136
139	Direct mutagenesis of Ha-ras-1 oncogenes by N-nitroso-N-methylurea during initiation of mammary carcinogenesis in rats. <i>Nature</i> , 1985, 315, 382-385.	13.7	872
140	Induction of mammary carcinomas in rats by nitroso-methylurea involves malignant activation of H-ras-1 locus by single point mutations. <i>Nature</i> , 1983, 306, 658-661.	13.7	736
141	Transforming genes in human tumors. <i>Journal of Cellular Biochemistry</i> , 1982, 20, 51-61.	1.2	63
142	T24 human bladder carcinoma oncogene is an activated form of the normal human homologue of BALB- and Harvey-MSV transforming genes. <i>Nature</i> , 1982, 298, 343-347.	13.7	616
143	A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. <i>Nature</i> , 1982, 300, 149-152.	13.7	1,369
144	Oncogenes in solid human tumours. <i>Nature</i> , 1982, 300, 539-542.	13.7	480

#	ARTICLE	IF	CITATIONS
145	Localization of the normal allele of T24 human bladder carcinoma oncogene to chromosome 11. Nature, 1982, 300, 773-774.	13.7	105
146	Evolutionary relationships between gag gene-coded proteins of murine and primate endogenous type C RNA viruses. Cell, 1977, 10, 641-648.	13.5	66
147	Differential Synthesis of Mammalian Type C Viral Gene Products in Infected Cells. Journal of Virology, 1977, 24, 1-7.	1.5	8
148	gag Gene of mammalian type-C RNA tumour viruses. Nature, 1976, 262, 554-559.	13.7	242